- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
- CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
More ▼
Key statistics
On Friday, Cytosorbents Corp (HQE1:STU) closed at 0.784, 9.34% above its 52-week low of 0.717, set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.781 |
---|---|
High | 0.784 |
Low | 0.781 |
Bid | 0.751 |
Offer | 0.814 |
Previous close | 0.777 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.31m |
Free float | 52.57m |
P/E (TTM) | -- |
Market cap | 45.68m USD |
EPS (TTM) | -0.5869 USD |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼